Increased NOX2 protein expression has been correlated with cardiac hypertrophy and dysfunction development via downregulation of PPARa, action that could be reversed with fenofibrate (a PPARa activator) or NOX2 inhibitors in in vitro and in vivo mice models [14]. Here, CYBB is linked to cardiac hypertrophy.